CVCarmen A. Vlahu

Carmen A. Vlahu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carmen A. Vlahu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • New Insights into the Effects of Chronic Kidney Failure and Dialysate Exposure on the Peritoneum

    by Carmen A. Vlahu, Jan Aten, Marijke de Graaff, Henk van Veen, Vincent Everts, Dirk R. de Waart, Dirk G. Struijk, Raymond T. Krediet

    Introduction: Chronic uremia and the exposure to dialysis solutions during peritoneal dialysis (PD) induce peritoneal alterations. Using a long-term peritoneal exposure model, we compared the effects of chronic kidney failure (CKD) itself and exposure to either a ‘conventional’ or a ‘biocompatible’ dialysis solution on peritoneal morphology and function. Methods: Wistar rats (Harlan, Zeist, the Netherlands) were grouped into: normal kidney function (NKF), CKD induced by 70% nephrectomy, CKD receiving daily peritoneal infusions with 3.86% glucose Dianeal (CKDD), or Physioneal (both solutions from Baxter Healthcare, Castlebar, Ireland) (CKDP). At 16 weeks, a peritoneal function test was performed, and histology, ultrastructure, and hydroxyproline content of peritoneal tissue were assessed. Results: Comparing CKD with NKF, peritoneal transport rates were higher, mesothelial cells (MC) displayed increased number of microvilli, blood and lymph vasculature expanded, vascular basal lamina appeared thicker, with limited areas of duplication, and fibrosis had developed. All alterations, except lymphangiogenesis, were enhanced by exposure to both dialysis fluids. Distinct MC alterations were observed in CKDD and CKDP, the latter displaying prominent basolateral protrusions. In addition, CKDP was associated with a trend towards less fibrosis compared to CKDD. Conclusions: Chronic kidney failure itself induced peritoneal alterations, which were in part augmented by exposure to glucose-based dialysis solutions. Overall, the conventional and biocompatible solutions had similar long-term effects on the peritoneum. Importantly, the latter may attenuate the development of fibrosis.


  • Open Access

    CKD pathophysiology and complications

    by Carmen A. Vlahu, Liffert Vogt, Dick G. Struijk, Hans Vink, Raymond T. Krediet, Noriaki Kurita, Akiko Fujii, Nagaaki Kotera, Mototsugu Tanaka, Shinji Tanaka, et al.

    Introduction and Aims: Dialysis patients have loss of glycocalyx barrier properties and increased levels of its constituents in blood. The endothelial glycocalyx is a negatively charged mesh of glycoproteins, proteoglycans and glycosaminoglycans lining the luminal side of blood vessels. It is able to reversibly bind positively charged sodium ions from circulation and might act as a sodium buffer. As a consequence, a reduction in the negatively charged components of the glycocalyx might result in an alteration in its sodium buffering capacity. Our aim was to investigate the role of the endothelial glycocalyx in sodium and fluid overload in hemodialysis patients.


  • Open Access

    Damage of the Endothelial Glycocalyx in Dialysis Patients

    by Carmen A. Vlahu, Bregtje A. Lemkes, Dirk G. Struijk, Marion G. Koopman, Raymond T. Krediet, Hans Vink

    Damage to the endothelial glycocalyx, which helps maintain vascular homeostasis, heightens the sensitivity of the vasculature to atherogenic stimuli. Patients with renal failure have endothelial dysfunction and increased risk for cardiovascular morbidity and mortality, but the state of the endothelial glycocalyx in these patients is unknown. Here, we used Sidestream Darkfield imaging to detect changes in glycocalyx dimension in dialysis patients and healthy controls from in vivo recordings of the sublingual microcirculation. Dialysis patients had increased perfused boundary region and perfused diameters, consistent with deeper penetration of erythrocytes into glycocalyx, indicating a loss of glycocalyx barrier properties. These patients also had higher serum levels of the glycocalyx constituents hyaluronan and syndecan-1 and increased hyaluronidase activity, suggesting the shedding of these components. Loss of residual renal function had no influence on the imaging parameters but did associate with greater shedding of hyaluronan in blood. Furthermore, patients with higher levels of inflammation had more significant damage to the glycocalyx barrier. In conclusion, these data suggest that dialysis patients have an impaired glycocalyx barrier and shed its constituents into blood, likely contributing to the sustained endothelial cell activation observed in ESRD.